Avoro Capital Advisors MRSN Position
Exited11-Fund ConvergenceAvoro Capital Advisors exited their position in Mersana Therapeutics Inc. (MRSN) in Q3 2023, after holding the stock for 3 quarters.
The position was first reported in Q1 2023 and has been tracked across 3 quarterly 13F filings.
MRSN is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Mersana Therapeutics Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Full company profile →Avoro Capital Advisors MRSN Position History
Frequently Asked Questions
Does Avoro Capital Advisors own MRSN?
No. Avoro Capital Advisors exited their position in Mersana Therapeutics Inc. (MRSN) in Q3 2023. They previously held the stock for 3 quarters.
How many hedge funds own MRSN?
11 specialist biotech hedge funds currently hold MRSN, including EcoR1 Capital, OrbiMed Advisors, Rock Springs Capital and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy MRSN?
Avoro Capital Advisors's position in MRSN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's MRSN position increasing or decreasing?
Avoro Capital Advisors completely exited their MRSN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MRSNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →